- ►diabetesjournals.org B Elbrønd, G Jakobsen, S Larsen, H Agersø, LB … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a double-blind, randomized dose, escalation,
placebo-controlled study, healthy male subjects were enrolled at eight consecutive dose levels
(1.25, 2.5, 5.0, 10.0, 12.5, 15.0, 17.5, and 20.0 μg/kg) with eight subjects per dose level at ... Cited by 103 - Related articles - BL Direct - All 6 versions
- ►pubget.com [PDF] H Agersø, LB Jensen, B Elbrønd, P Rolan, M … - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like peptide-1 (GLP-1), a polypeptide hormone secreted by the
l-cells in the gastrointestinal tract, has shown promising effects as a new treatment modality for
patients with Type II (non-insulin-dependent) diabetes mellitus. However, the ... Cited by 168 - Related articles - BL Direct - All 5 versions
JG Kim, LL Baggio, DP Bridon, JP Castaigne, MF … - Diabetes, 2003 - Am Diabetes Assoc The rapid degradation of native glucagon-like peptide 1 (GLP-1) by dipeptidyl peptidase-IV
(DPP-IV) has fostered new approaches for generation of degradation-resistant GLP-1
analogues. We examined the biological activity of CJC-1131, a DPP-IV-resistant drug ... Cited by 127 - Related articles - BL Direct - All 5 versions
CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H Agersø, … - Diabetes, 2002 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential interest for the
treatment of type 2 diabetes. To evaluate actions of NN2211, a long-acting GLP-1 derivative,
we examined 11 patients with type 2 diabetes, age 59 ± 7 years (mean ± SD), BMI 28.9 ± ... Cited by 175 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org S Madsbad, O Schmitz, J Ranstam, G Jakobsen, … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A double-blind, randomized, parallel-group,
placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients
with type 2 diabetes. The mean age was 56.6 years and the mean HbA 1c was 7.6% ... Cited by 170 - Related articles - BL Direct - All 6 versions
- ►physiology.org B Rolin, MO Larsen, CF Gotfredsen, CF … - American Journal of …, 2002 - Am Physiological Soc NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1) derivative designed
for once daily administration in humans. NN2211 dose dependently reduced the glycemic levels
in ob/ob mice, with antihyperglycemic activity still evident 24 h postdose. Apart from an ... Cited by 130 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org LL Baggio, Q Huang, TJ Brown, DJ Drucker - Diabetes, 2004 - Am Diabetes Assoc Peptide hormones exert unique actions via specific G protein–coupled receptors; however, the
therapeutic potential of regulatory peptides is frequently compromised by rapid enzymatic inactivation
and clearance from the circulation. In contrast, recombinant or covalent coupling of ... Cited by 96 - Related articles - BL Direct - All 11 versions
LB Knudsen, PF Nielsen, PO Huusfeldt, NL Johansen, … - J. Med. Chem, 2000 - pubs.acs.org A series of very potent derivatives of the 30-amino acid peptide hormone glucagon-like
peptide-1 (GLP-1) is described. The compounds were all derivatized with fatty acids in order
to protract their action by facilitating binding to serum albumin. GLP-1 had a potency (EC ... Cited by 136 - Related articles - All 5 versions
AM Chang, G Jakobsen, J Sturis, MJ Smith, CJ Bloem, … - Diabetes, 2003 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion in a glucose-dependent
manner, but its short half-life limits its therapeutic potential. We tested NN2211, a long-acting
GLP-1 derivative, in 10 subjects with type 2 diabetes (means ± SD: age 63 ± 8 years, BMI ... Cited by 94 - Related articles - BL Direct - All 9 versions
MA Nauck, M Hompesch, R Filipczak, TD Le, … - … clinical endocrinology & …, 2006 - ncbi.nlm.nih.gov AIMS: Effects of the long acting GLP-1 analogue--liraglutide in subjects with type 2 diabetes.
METHODS: 144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised
to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or ... Cited by 59 - Related articles - BL Direct - All 5 versions
